Skip to main
SRPT

Sarepta Therapeutics (SRPT) Stock Forecast & Price Target

Sarepta Therapeutics (SRPT) Analyst Ratings

Based on 26 analyst ratings
Hold
Strong Buy 12%
Buy 27%
Hold 46%
Sell 4%
Strong Sell 12%

Bulls say

Sarepta Therapeutics Inc has reported a steady number of start forms for its approved treatments, indicating potential for annual sales to exceed the $500 million mark, driven by consistent adoption of its PMO products. The preliminary net revenue of $259.2 million for 4Q25, reflecting a 9% increase from the previous quarter, signifies stable market traction and suggests that recent study data have not negatively impacted payer coverage. Additionally, upcoming Ph1/2 data from new programs in 1Q26 could enhance the company’s growth prospects and reinforce confidence in its pipeline, potentially leading to further revenue increases if results support competitive profiles for its therapeutic candidates.

Bears say

Sarepta Therapeutics's recent preliminary net revenue for Elevidys in 4Q25 fell short of consensus estimates, indicating potential weaknesses in commercial performance and highlighting concerns over franchise fragility due to reliance on a small number of patient treatments. Despite management's optimism about future sales growth and a significant expansion of their salesforce, there are growing doubts regarding the efficacy and safety of Elevidys, which may hinder demand amid increasing competition from emerging therapies. Furthermore, the anticipated loss of patent protection on marketed products contributes to an unfavorable outlook, reflected in the projected 2% annual decline in revenues beyond 2026, suggesting that long-term growth prospects may be limited.

Sarepta Therapeutics (SRPT) has been analyzed by 26 analysts, with a consensus rating of Hold. 12% of analysts recommend a Strong Buy, 27% recommend Buy, 46% suggest Holding, 4% advise Selling, and 12% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sarepta Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sarepta Therapeutics (SRPT) Forecast

Analysts have given Sarepta Therapeutics (SRPT) a Hold based on their latest research and market trends.

According to 26 analysts, Sarepta Therapeutics (SRPT) has a Hold consensus rating as of Apr 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sarepta Therapeutics (SRPT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.